Paul Grootendorst - Publications

Pharmaceutical Sciences University of Toronto, Toronto, ON, Canada 
Public Health, Epidemiology, Commerce-Business Economics

0/93 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches
2020 Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, Anis AH. The Impact of Tiered-Pricing Framework on Generic Entry in Canada. International Journal of Health Policy and Management. PMID 33233033 DOI: 10.34172/ijhpm.2020.215  0.01
2020 Zhang W, Guh DP, Sun H, Lynd LD, Hollis A, Grootendorst P, Anis AH. Factors associated with drug shortages in Canada: a retrospective cohort study. Cmaj Open. 8: E535-E544. PMID 32873582 DOI: 10.9778/cmajo.20200036  0.01
2020 Loiacono MM, Mitsakakis N, Kwong JC, Gomez GB, Chit A, Grootendorst P. Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England. Jama Network Open. 3: e207743. PMID 32597991 DOI: 10.1001/jamanetworkopen.2020.7743  0.01
2020 Bereza BG, Coyle D, So DY, Kadziola Z, Wells G, Grootendorst P, Papadimitropoulos EA. Stated Preferences for Attributes of a Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario. Clinicoeconomics and Outcomes Research : Ceor. 12: 167-175. PMID 32256091 DOI: 10.2147/CEOR.S234298  0.01
2020 Loiacono MM, Mahmud SM, Chit A, van Aalst R, Kwong JC, Mitsakakis N, Skinner L, Thommes E, Bricout H, Grootendorst P. Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. Vaccine: X. 4: 100054. PMID 32072152 DOI: 10.1016/j.jvacx.2020.100054  0.01
2019 Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. Bmj Open. 9: e027491. PMID 31719068 DOI: 10.1136/bmjopen-2018-027491  0.01
2019 Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 31509639 DOI: 10.1111/liv.14247  0.01
2019 Grootendorst P, Ranjithan R. Pharmacists should counsel users of medical cannabis, but should they be dispensing it? Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 152: 10-13. PMID 30719190 DOI: 10.1177/1715163518814273  0.01
2019 Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases. 14: 12. PMID 30630499 DOI: 10.1186/s13023-018-0990-4  0.01
2018 Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Health Services : Planning, Administration, Evaluation. 20731418789610. PMID 30040005 DOI: 10.1177/0020731418789610  0.01
2018 Grootendorst P, Shim M, Tieu J. Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 151: 197-202. PMID 29796133 DOI: 10.1177/1715163518768009  0.01
2018 Choi SKY, Boyle E, Cairney J, Grootendorst P, Gardner S, Collins EJ, Kendall C, Rourke SB. Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study. Plos One. 13: e0195185. PMID 29630615 DOI: 10.1371/journal.pone.0195185  0.01
2017 Jayasundara K, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. Pharmacoeconomics - Open. 1: 167-173. PMID 29441496 DOI: 10.1007/s41669-017-0022-7  0.01
2017 Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, Wong WWL, Grootendorst P, Krahn MD. Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis. Journal of Viral Hepatitis. PMID 29239068 DOI: 10.1111/jvh.12846  0.01
2016 Eom G, Grootendorst P, Duffin J. The case for an essential medicines list for Canada. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. PMID 27297818 DOI: 10.1503/cmaj.160134  0.01
2016 Hamandi B, Husain S, Grootendorst P, Papadimitropoulos EA. Clinical and Microbiological Epidemiology of Early and Late Infectious Complications among Solid-Organ Transplant Recipients Requiring Hospitalization. Transplant International : Official Journal of the European Society For Organ Transplantation. PMID 27284994 DOI: 10.1111/tri.12808  0.01
2016 Chit A, Lee JK, Shim M, Nguyen VH, Grootendorst P, Wu J, Van Exan R, Langley JM. Economic Evaluation of Vaccines in Canada: A Systematic Review. Human Vaccines & Immunotherapeutics. 0. PMID 26890128 DOI: 10.1080/21645515.2015.1137405  0.01
2015 Hollis A, Grootendorst P. Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. Healthcare Policy = Politiques De Santé. 11: 10-4. PMID 26571465  0.01
2015 Choi SK, Boyle E, Burchell AN, Gardner S, Collins E, Grootendorst P, Rourke SB. Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study. Plos One. 10: e0142706. PMID 26566285 DOI: 10.1371/journal.pone.0142706  0.01
2015 Boutis K, von Keyserlingk C, Willan A, Narayanan UG, Brison R, Grootendorst P, Plint AC, Parker M, Goeree R. Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments. Annals of Emergency Medicine. 66: 455-463.e4. PMID 26187612 DOI: 10.1016/j.annemergmed.2015.05.027  0.01
2015 Grootendorst P. How Effective Is the Medicare Part D Drug Plan? Annals of Internal Medicine. 162: 869-70. PMID 26075759 DOI: 10.7326/M15-0953  0.01
2015 Li Y, Abbaspour MR, Grootendorst PV, Rauth AM, Wu XY. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 94: 170-9. PMID 25986587 DOI: 10.1016/j.ejpb.2015.04.028  0.01
2015 Chit A, Chit A, Papadimitropoulos M, Krahn M, Parker J, Grootendorst P. The opportunity cost of capital: development of new pharmaceuticals. Inquiry : a Journal of Medical Care Organization, Provision and Financing. 52. PMID 25933615 DOI: 10.1177/0046958015584641  0.01
2015 Nguyen HV, Grootendorst P. Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada. Tobacco Control. 24: 382-8. PMID 24610053 DOI: 10.1136/tobaccocontrol-2013-051387  0.01
2015 Shajarizadeh A, Grootendorst P, Hollis A. Newton’s First Law as Applied to Pharmacies: Why Entry Order Matters for Generics International Journal of the Economics of Business. 22: 201-217. DOI: 10.1080/13571516.2015.1045746  0.01
2014 Chit A, Parker J, Halperin SA, Papadimitropoulos M, Krahn M, Grootendorst P. Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. Vaccine. 32: 3336-40. PMID 23830976 DOI: 10.1016/j.vaccine.2013.06.055  0.01
2014 Piérard E, Grootendorst P. Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada Applied Economics. 46: 1081-1092. DOI: 10.1080/00036846.2013.866204  0.01
2013 de Oliveira C, Nguyen HV, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD. Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. Cmaj Open. 1: E83-90. PMID 25077108 DOI: 10.9778/cmajo.20130003  0.01
2013 Boutis K, Grootendorst P, Willan A, Plint AC, Babyn P, Brison RJ, Sayal A, Parker M, Mamen N, Schuh S, Grimshaw J, Johnson D, Narayanan U. Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 185: E731-8. PMID 23939215 DOI: 10.1503/cmaj.122050  0.01
2013 Nguyen HV, de Oliveira C, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD. Canada's contribution to global research in cardiovascular diseases. The Canadian Journal of Cardiology. 29: 742-6. PMID 23219608 DOI: 10.1016/j.cjca.2012.09.013  0.01
2012 Grootendorst P, Bouchard R, Hollis A. Canada's laws on pharmaceutical intellectual property: the case for fundamental reform. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 184: 543-9. PMID 22065362 DOI: 10.1503/cmaj.110493  0.01
2012 Grootendorst P. Prescription drug insurance and reimbursement The Elgar Companion to Health Economics, Second Edition. 114-122. DOI: 10.4337/9781849802673.00021  0.01
2012 Christopher Auld M, Grootendorst P. Challenges for Causal Inference in Obesity Research The Oxford Handbook of the Social Science of Obesity. DOI: 10.1093/oxfordhb/9780199736362.013.0014  0.01
2011 McLeod L, Bereza BG, Shim M, Grootendorst P. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal. 5: e1-9. PMID 22046212  0.01
2011 Faulkner GE, Grootendorst P, Nguyen VH, Andreyeva T, Arbour-Nicitopoulos K, Auld MC, Cash SB, Cawley J, Donnelly P, Drewnowski A, Dubé L, Ferrence R, Janssen I, Lafrance J, Lakdawalla D, et al. Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey. The International Journal of Behavioral Nutrition and Physical Activity. 8: 109. PMID 21978599 DOI: 10.1186/1479-5868-8-109  0.01
2011 Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety. 20: 838-48. PMID 21688345 DOI: 10.1002/pds.2132  0.01
2011 Quiñonez C, Grootendorst P. Equity in dental care among Canadian households. International Journal For Equity in Health. 10: 14. PMID 21496297 DOI: 10.1186/1475-9276-10-14  0.01
2011 Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy (Amsterdam, Netherlands). 100: 4-17. PMID 21256615 DOI: 10.1016/j.healthpol.2010.12.002  0.01
2011 Grootendorst P, Hollis A, Levine DK, Pogge T, Edwards AM. New approaches to rewarding pharmaceutical innovation. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 183: 681-5. PMID 21149519 DOI: 10.1503/cmaj.100375  0.01
2011 Grootendorst P, Hollis A. The 2011 Canada-European Union Comprehensive Economic and Trade Agreement: An economic impact assessment of the EU's proposed pharmaceutical intellectual property provisions Journal of Generic Medicines. 8: 81-103. DOI: 10.1177/1741134311408275  0.01
2009 Grootendorst P, Piérard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Review of Pharmacoeconomics & Outcomes Research. 9: 353-64. PMID 19670996 DOI: 10.1586/erp.09.35  0.01
2009 Grootendorst P. How should we support pharmaceutical innovation? Expert Review of Pharmacoeconomics & Outcomes Research. 9: 313-20. PMID 19670991 DOI: 10.1586/erp.09.34  0.01
2009 Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 847-56. PMID 19490554 DOI: 10.1111/j.1524-4733.2009.00532.x  0.01
2009 Grootendorst P, Piérard E, Shim M. Response to Lichtenberg Expert Review of Pharmacoeconomics and Outcomes Research. 9: 505-508. DOI: 10.1586/erp.09.65  0.01
2009 Grootendorst P, Piérard E, Shim M. Life expectancy gains from pharmaceutical drugs: A critical appraisal of the literature (Expert Review of Pharmacoeconomics and Outcomes Research 9, 4, 353-364 (2009)) Expert Review of Pharmacoeconomics and Outcomes Research. 9: 492. DOI: 10.1586/erp.09.51  0.01
2008 Marshall D, Pericak D, Grootendorst P, Gooch K, Faris P, Frank C, Bellamy N, Torrance G, Feeny D. Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 470-7. PMID 18489670 DOI: 10.1111/j.1524-4733.2007.00258.x  0.01
2008 Johnston KM, Gustafson P, Levy AR, Grootendorst P. Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Statistics in Medicine. 27: 1539-56. PMID 17847052 DOI: 10.1002/sim.3036  0.01
2008 Bhatti TA, Einarson T, Austin Z, Grootendorst P. The impact of financial incentives on pharmacist dispensing habits: Evidence from the british columbia product incentive plan Journal of Pharmaceutical Finance, Economics and Policy. 16: 35-56. DOI: 10.1080/15385690801963464  0.01
2007 Grootendorst P, Di Matteo L. Response to pazderka and schroeder. Healthcare Policy = Politiques De Santé. 2: 95-6. PMID 19305723  0.01
2007 Grootendorst P, Matteo LD. The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada. Healthcare Policy = Politiques De Santé. 2: 63-84. PMID 19305720  0.01
2007 Bennett HA, Boon HS, Romans SE, Grootendorst P. Becoming the best mom that I can: women's experiences of managing depression during pregnancy--a qualitative study. Bmc Women's Health. 7: 13. PMID 17848199 DOI: 10.1186/1472-6874-7-13  0.01
2007 Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, Sheehy OE, Warren L, Sykora K, Rahme E. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy (Amsterdam, Netherlands). 84: 1-13. PMID 17570558 DOI: 10.1016/j.healthpol.2007.04.010  0.01
2007 Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J. Effect of copayments on drug use in the presence of annual payment limits. The American Journal of Managed Care. 13: 328-34. PMID 17567233  0.01
2007 Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW. A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. The Journal of Rheumatology. 34: 534-42. PMID 17343301  0.01
2007 Bhatti T, Rana Z, Grootendorst P. Dental insurance, income and the use of dental care in Canada. Journal (Canadian Dental Association). 73: 57. PMID 17295945  0.01
2007 Austin PC, Grootendorst P, Normand SL, Anderson GM. Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Statistics in Medicine. 26: 754-68. PMID 16783757 DOI: 10.1002/sim.2618  0.01
2007 Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statistics in Medicine. 26: 734-53. PMID 16708349 DOI: 10.1002/sim.2580  0.01
2007 Grootendorst P. A review of instrumental variables estimation of treatment effects in the applied health sciences Health Services and Outcomes Research Methodology. 7: 159-179. DOI: 10.1007/s10742-007-0023-6  0.01
2007 Autin PC, Grootendorst P, Normand SLT, Anderson GM. Author's reply [4] Statistics in Medicine. 26: 3210-3212. DOI: 10.1002/sim.2880  0.01
2006 Marshall DA, McGeer A, Gough J, Grootendorst P, Buitendyk M, Simonyi S, Green K, Jaszewski B, MacLeod SM, Low DE. Impact of antibiotic administrative restrictions on trends in antibiotic resistance. Canadian Journal of Public Health = Revue Canadienne De Santé Publique. 97: 126-31. PMID 16620000  0.01
2006 Grootendorst P, Stewart D. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Economics. 15: 735-42. PMID 16498702 DOI: 10.1002/hec.1103  0.01
2006 Marshall D, Gough J, Grootendorst P, Buitendyk M, Jaszewski B, Simonyi S, Jivraj F, Macleod S. Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. Journal of Health Services Research & Policy. 11: 13-20. PMID 16378528 DOI: 10.1258/135581906775094253  0.01
2006 Marshall CD, Amin H, Kovacs KM, Lydersen C. Microstructure and innervation of the mystacial vibrissal follicle-sinus complex in bearded seals, Erignathus barbatus (Pinnipedia: Phocidae). The Anatomical Record. Part a, Discoveries in Molecular, Cellular, and Evolutionary Biology. 288: 13-25. PMID 16342212 DOI: 10.1002/ar.a.20273  0.01
2006 Grootendorst P. Disclosure of physician prescribing information and prescription drug costs evidence from Saskatchewan Journal of Pharmaceutical Marketing and Management. 17: 61-87. DOI: 10.1300/J058v17n02_06  0.01
2005 Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K. Can current electronic systems meet drug safety and effectiveness requirements? Amia ... Annual Symposium Proceedings / Amia Symposium. Amia Symposium. 335-9. PMID 16779057  0.01
2005 Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Services Research. 40: 1297-317. PMID 16174135 DOI: 10.1111/j.1475-6773.2005.00420.x  0.01
2005 Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Economics. 14: 909-23. PMID 16127675 DOI: 10.1002/hec.1041  0.01
2005 Grootendorst PV, Veall MR. National catastrophic drug insurance revisited: Who would benefit from senator Kirby's recommendations? Canadian Public Policy. 31: 341-358. DOI: 10.2307/3552355  0.01
2005 Alan S, Crossley TF, Grootendorst P, Veall MR. Distributional effects of 'general population' prescription drug programs in Canada Canadian Journal of Economics. 38: 128-148. DOI: 10.1111/j.0008-4085.2005.00272.x  0.01
2004 Marshall DA, McGeer AJ, Jaszewski BA, Grootendorst PV, Green KA, Laframboise MF, Lam LA, Low DE, MacLeod SM. Resistance to antibiotics: administrative response to the challenge. Managed Care Interface. 17: 20-9. PMID 15656376  0.01
2004 Auld MC, Grootendorst P. An empirical analysis of milk addiction. Journal of Health Economics. 23: 1117-33. PMID 15556239 DOI: 10.1016/j.jhealeco.2004.02.003  0.01
2004 Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care. 42: 653-60. PMID 15213490 DOI: 10.1097/01.mlr.0000129497.10930.a2  0.01
2004 Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. International Journal of Health Services : Planning, Administration, Evaluation. 34: 101-22. PMID 15088676 DOI: 10.2190/4M3E-L0YF-W1TD-EKG0  0.01
2004 Grootendorst P. The impact of an on-line pharmacy claims adjudication network on use and costs of prescription drugs: Evidence from British Columbia Pharmacare Journal of Pharmaceutical Finance, Economics and Policy. 13: 27-39. DOI: 10.1300/J371v13n03_03  0.01
2003 Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 10: 67-71. PMID 12879144  0.01
2003 Grootendorst P, Newman EC, Levine MA. Validity of self-reported prescription drug insurance coverage. Health Reports. 14: 35-46. PMID 12658863  0.01
2003 Grootendorst P, Palfrey D, Willison D, Hurley J. A review of the comprehensiveness of provincial drug coverage for Canadian seniors Canadian Journal On Aging. 22: 33-44.  0.01
2002 Duggan AE, Westbrook J. Restricted access for PPIs not a panacea. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 167: 1102; author reply 1. PMID 12427695  0.01
2002 Alan S, Crossley TF, Grootendorst P, Veall MR. The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada. Journal of Health Economics. 21: 805-26. PMID 12349883 DOI: 10.1016/S0167-6296(02)00012-7  0.01
2002 Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 9: 79-99. PMID 12172588  0.01
2002 Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 166: 1655-62. PMID 12126319  0.01
2001 Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 165: 1011-9. PMID 11699696  0.01
2001 Schneeweiss S, Maclure M, Walker AM, Grootendorst P, Soumerai SB. On the evaluation of drug benefits policy changes with longitudinal claims data: The policy maker's versus the clinician's perspective Health Policy. 55: 97-109. PMID 11163649 DOI: 10.1016/S0168-8510(00)00120-2  0.01
2000 Grootendorst P. Censoring in statistical models of health status: What happens when one can do better than '1' Quality of Life Research. 9: 911-914. PMID 11284210 DOI: 10.1023/A:1008938429316  0.01
2000 Grootendorst P, Feeny D, Furlong W. Health Utilities Index Mark 3: Evidence of construct validity for stroke and arthritis in a population health survey Medical Care. 38: 290-299. PMID 10718354  0.01
2000 Levine MAH, Grootendorst P. Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy Pharmacoepidemiology and Drug Safety. 9: 367-370. DOI: 10.1002/1099-1557(200009/10)9:5<367::AID-PDS515>3.0.CO;2-O  0.01
1999 Grootendorst P, Holbrook A. Evaluating the impact of reference-based pricing Cmaj. 161: 273-274. PMID 10463048  0.01
1997 Grootendorst PV. Health care policy evaluation using longitudinal insurance claims data: An application of the panel Tobit estimator Health Economics. 6: 365-382. PMID 9285230 DOI: 10.1002/(SICI)1099-1050(199707)6:4<365::AID-HEC279>3.0.CO;2-E  0.01
1997 Holbrook A, O'Brien B, Grootendorst P. Reference-based pricing (RBP) of prescription drugs The Canadian Journal of Cardiology. 13: 689-690. PMID 9251582  0.01
1997 Grootendorst PV, Feeny DH, Furlong W. Does it matter whom and how you ask? Inter- and intra-rater agreement in the Ontario Health Survey Journal of Clinical Epidemiology. 50: 127-135. PMID 9120505 DOI: 10.1016/S0895-4356(96)00314-9  0.01
1997 Grootendorst PV, O'Brien BJ, Anderson GM. On becoming 65 in Ontario. Effects of drug plan eligibility on use of prescription medicines. Medical Care. 35: 386-98. PMID 9107206  0.01
1995 Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD) Clinical and Investigative Medicine. 18: 455-464. PMID 8714789  0.01
1995 Grootendorst PV. A comparison of alternative models of prescription drug utilization Health Economics. 4: 183-198. PMID 7550769  0.01
Hide low-probability matches.